vs
Arcellx, Inc.（ACLX）与艾伯维（ARGX）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Arcellx, Inc.的1495.5倍（$2.5B vs $1.7M）。艾伯维净利率更高（35.5% vs -3513.4%，领先3548.9%）。艾伯维同比增速更快（83.2% vs -89.2%）。艾伯维自由现金流更多（$322.4M vs $-58.9M）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
ACLX vs ARGX — 直观对比
营收规模更大
ARGX
是对方的1495.5倍
$1.7M
营收增速更快
ARGX
高出172.4%
-89.2%
净利率更高
ARGX
高出3548.9%
-3513.4%
自由现金流更多
ARGX
多$381.3M
$-58.9M
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $2.5B |
| 净利润 | $-58.1M | $877.2M |
| 毛利率 | — | 89.5% |
| 营业利润率 | -3850.2% | 28.9% |
| 净利率 | -3513.4% | 35.5% |
| 营收同比 | -89.2% | 83.2% |
| 净利润同比 | -23.4% | 1.3% |
| 每股收益（稀释后） | $-1.01 | $13.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXARGX
| Q4 25 | $1.7M | $2.5B | ||
| Q3 25 | $4.9M | — | ||
| Q2 25 | $7.6M | $1.8B | ||
| Q1 25 | $8.1M | — | ||
| Q4 24 | $15.3M | $1.4B | ||
| Q3 24 | $26.0M | — | ||
| Q2 24 | $27.4M | $901.9M | ||
| Q1 24 | $39.3M | — |
净利润ACLXARGX
| Q4 25 | $-58.1M | $877.2M | ||
| Q3 25 | $-55.8M | — | ||
| Q2 25 | $-52.8M | $414.8M | ||
| Q1 25 | $-62.3M | — | ||
| Q4 24 | $-47.1M | $865.6M | ||
| Q3 24 | $-25.9M | — | ||
| Q2 24 | $-27.2M | $-32.5M | ||
| Q1 24 | $-7.2M | — |
毛利率ACLXARGX
| Q4 25 | — | 89.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 89.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 90.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 89.4% | ||
| Q1 24 | — | — |
营业利润率ACLXARGX
| Q4 25 | -3850.2% | 28.9% | ||
| Q3 25 | -1248.3% | — | ||
| Q2 25 | -777.4% | 19.2% | ||
| Q1 25 | -847.6% | — | ||
| Q4 24 | -348.2% | 8.7% | ||
| Q3 24 | -129.1% | — | ||
| Q2 24 | -127.8% | -15.4% | ||
| Q1 24 | -40.3% | — |
净利率ACLXARGX
| Q4 25 | -3513.4% | 35.5% | ||
| Q3 25 | -1127.1% | — | ||
| Q2 25 | -698.6% | 23.4% | ||
| Q1 25 | -766.0% | — | ||
| Q4 24 | -308.4% | 64.1% | ||
| Q3 24 | -99.4% | — | ||
| Q2 24 | -99.3% | -3.6% | ||
| Q1 24 | -18.3% | — |
每股收益（稀释后）ACLXARGX
| Q4 25 | $-1.01 | $13.25 | ||
| Q3 25 | $-0.99 | — | ||
| Q2 25 | $-0.94 | $6.32 | ||
| Q1 25 | $-1.13 | — | ||
| Q4 24 | $-0.87 | $13.33 | ||
| Q3 24 | $-0.48 | — | ||
| Q2 24 | $-0.51 | $-0.55 | ||
| Q1 24 | $-0.14 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $3.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $402.4M | $7.3B |
| 总资产 | $604.0M | $8.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACLXARGX
| Q4 25 | $450.3M | $3.5B | ||
| Q3 25 | $461.4M | — | ||
| Q2 25 | $453.1M | $2.1B | ||
| Q1 25 | $543.3M | — | ||
| Q4 24 | $587.4M | $1.5B | ||
| Q3 24 | $574.3M | — | ||
| Q2 24 | $516.7M | $1.4B | ||
| Q1 24 | $573.9M | — |
总债务ACLXARGX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | — |
股东权益ACLXARGX
| Q4 25 | $402.4M | $7.3B | ||
| Q3 25 | $440.8M | — | ||
| Q2 25 | $392.2M | $6.1B | ||
| Q1 25 | $416.9M | — | ||
| Q4 24 | $454.8M | $5.5B | ||
| Q3 24 | $483.0M | — | ||
| Q2 24 | $487.2M | $4.3B | ||
| Q1 24 | $496.6M | — |
总资产ACLXARGX
| Q4 25 | $604.0M | $8.7B | ||
| Q3 25 | $655.9M | — | ||
| Q2 25 | $619.1M | $7.2B | ||
| Q1 25 | $648.1M | — | ||
| Q4 24 | $711.3M | $6.2B | ||
| Q3 24 | $764.9M | — | ||
| Q2 24 | $734.3M | $4.8B | ||
| Q1 24 | $779.7M | — |
负债/权益比ACLXARGX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $323.3M |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | $322.4M |
| 自由现金流率自由现金流/营收 | -3563.4% | 13.0% |
| 资本支出强度资本支出/营收 | 46.2% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 0.37× |
| 过去12个月自由现金流最近4个季度 | $-212.6M | $594.5M |
8季度趋势，按日历期对齐
经营现金流ACLXARGX
| Q4 25 | $-58.2M | $323.3M | ||
| Q3 25 | $-49.2M | — | ||
| Q2 25 | $-39.7M | $361.8M | ||
| Q1 25 | $-63.1M | — | ||
| Q4 24 | $-46.0M | $41.9M | ||
| Q3 24 | $30.7M | — | ||
| Q2 24 | $-36.2M | $-124.7M | ||
| Q1 24 | $-31.9M | — |
自由现金流ACLXARGX
| Q4 25 | $-58.9M | $322.4M | ||
| Q3 25 | $-49.5M | — | ||
| Q2 25 | $-40.2M | $356.6M | ||
| Q1 25 | $-63.9M | — | ||
| Q4 24 | $-47.5M | $40.9M | ||
| Q3 24 | $28.4M | — | ||
| Q2 24 | $-39.5M | $-125.5M | ||
| Q1 24 | $-38.3M | — |
自由现金流率ACLXARGX
| Q4 25 | -3563.4% | 13.0% | ||
| Q3 25 | -1000.3% | — | ||
| Q2 25 | -532.4% | 20.1% | ||
| Q1 25 | -786.4% | — | ||
| Q4 24 | -311.3% | 3.0% | ||
| Q3 24 | 109.2% | — | ||
| Q2 24 | -144.1% | -13.9% | ||
| Q1 24 | -97.7% | — |
资本支出强度ACLXARGX
| Q4 25 | 46.2% | 0.0% | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 6.4% | 0.3% | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 9.8% | 0.1% | ||
| Q3 24 | 8.8% | — | ||
| Q2 24 | 11.7% | 0.1% | ||
| Q1 24 | 16.4% | — |
现金转化率ACLXARGX
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
